Mutations in BRCA2 and taxane resistance in prostate cancer

Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Nientiedt, Cathleen, Heller, Martina, Endris, Volker, Volckmar, Anna-Lena, Zschäbitz, Stefanie, Tapia-Laliena, María A., Duensing, Anette, Jäger, Dirk, Schirmacher, Peter, Sültmann, Holger, Stenzinger, Albrecht, Hohenfellner, Markus, Grüllich, Carsten, Duensing, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496866/
https://www.ncbi.nlm.nih.gov/pubmed/28676659
http://dx.doi.org/10.1038/s41598-017-04897-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496866/
https://www.ncbi.nlm.nih.gov/pubmed/28676659
http://dx.doi.org/10.1038/s41598-017-04897-x

Ejemplares similares